|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Company
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:acquisition
|
gptkb:Aclaris_Therapeutics
gptkb:Checkmate_Pharmaceuticals
gptkb:Alder_Bio_Pharmaceuticals
|
|
gptkbp:awards
|
gptkb:Nobel_Prize_in_Physiology_or_Medicine_(2020)
|
|
gptkbp:ceo
|
gptkb:Leonard_Schleifer
|
|
gptkbp:clinical_trial
|
gptkb:drug
ongoing
REGN-CO V2 efficacy
REGN-CO V2 in diverse populations
REGN-CO V2 in elderly patients
REGN-CO V2 in high-risk patients
REGN-CO V2 in hospitalized patients
REGN-CO V2 in immunocompromised patients
REGN-CO V2 in non-hospitalized patients
REGN-CO V2 safety
|
|
gptkbp:collaborated_with
|
gptkb:Roche
|
|
gptkbp:employees
|
Over 8000
approximately 8,000
|
|
gptkbp:focus
|
Drug Development
|
|
gptkbp:founded
|
gptkb:1988
|
|
gptkbp:founder
|
gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer
|
|
gptkbp:headquarters
|
gptkb:Tarrytown,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Regeneron
|
|
gptkbp:impact
|
COVID-19 symptoms
COVID-19 hospitalization rates
COVID-19 viral load
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:is_affected_by
|
gptkb:REGEN-COV
monoclonal antibodies
post-exposure prophylaxis
distribution partnerships
supply agreements
prevention of severe disease
REGN-CO V2
antibody cocktail
efficacy against variants
reduction in death rates
reduction in hospitalization
treatment for mild to moderate cases
|
|
gptkbp:key_people
|
gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer
|
|
gptkbp:language_of_instruction
|
COVID-19 therapies
|
|
gptkbp:notable_products
|
gptkb:Dupixent
gptkb:Eylea
gptkb:EYLEA
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:physicist
gptkb:U._S._government
gptkb:Sanofi
Partnership with Sanofi
|
|
gptkbp:partnerships
|
gptkb:physicist
gptkb:Sanofi
|
|
gptkbp:products
|
gptkb:Dupixent
gptkb:Regen-Cov
gptkb:Eylea
|
|
gptkbp:receives_funding_from
|
gptkb:U._S._Department_of_Health_and_Human_Services
gptkb:Operation_Warp_Speed
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:WHO
gptkb:EMA
|
|
gptkbp:research_focus
|
oncology
monoclonal antibodies
infectious diseases
immunology
genetic medicine
|
|
gptkbp:revenue
|
$8.5 billion (2020)
|
|
gptkbp:symbol
|
gptkb:REGN
|
|
gptkbp:technology
|
Genomic medicine
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
regeneron.com
|